Scientific publications
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma. Scientific Publication
Feb 22, 2024
| Magazine: Haematologica
Maria Victoria Mateos 1 , Katja Weisel 2 , Evangelos Terpos 3 , Sossana Delimpasi 4 , Efstathios Kastritis 3 , Elena Zamagni 5 , Michel Delforge 6 , Enrique Ocio 7 , Eirini Katodritou 8 , Francesca Gay 9 , Alessandra Larocca 9 , Xavier Leleu 10 , Paula Rodriguez Otero 11 , Fredik Schjesvold 12 , Michele Cavo 13 , Meletios A Dimopoulos 3
No abstract available
CITATION Haematologica. 2024 Feb 22. doi: 10.3324/haematol.2023.284694
![](/.resources/ModuloCUN/resources/img/publicaciones/icono-destacado-investigadores.png)